BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing
News | 04. 20. 2010
Liquidia Technologies
RESEARCH TRIANGLE PARK, N.C., April 20, 2010 --(EON: Enhanced Online News)-- Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.
